IHS Chemical Week

Markets :: Fine Chemicals/Biotech :: Pharmaceutical ingredients

Sun Pharma and Lupin receive FDA approvals for generic Cymbalta

7:34 AM MST | December 12, 2013 | Natasha Alperowicz

Sun Pharmaceutical Industries (Mumbai) and Lupin (Mumbai), two leading pharma producers for the global markets, announced today that their US subsidiaries have gained FDA approvals for duloxetine hydrochloride delayed release drug, the generic version of the antidepressant  Cymbalta.  Cymbalta delayed-release capsule 20, 30 and 60 mg is an Eli Lilly product with last year’s sales in the United States approaching $5.5 billion.   Sun Pharma in the year ended 31 March 2013 reported sales of $2.1 billion of which $1.1 billion were in the US...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week subscriber yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine a year in print or digital format
  • Real time news and analysis on chemweek.com 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now


contact us | about us | privacy policy | sitemap

ihsCopyright © IHS, Inc.All rights reserved.Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa